Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
13 results
  • Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer

18-418          Phase III

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Bladder Cancer

20-531          Phase II

A Multicenter, Single-Arm Open Label Phase II Trial of Cryoablation in Combination with Pembrolizumab or Avelumab in Patients with Metastatic Urothelial Carcinoma

  • Bladder Cancer

22-604          Phase I

A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)

  • Melanoma, Uterine Cancer, Lung Cancer, Endometrial Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Sarcoma, Pancreatic Cancer, Liver Cancer, Gastric (Stomach) Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

  • Gastric (Stomach) Cancer, Esophageal Cancer, Breast Cancer, Bladder Cancer, Lung Cancer, Ovarian Cancer

23-679          Phase II

A Phase 1/2 Study of PRO1107 in Patients with Advanced Solid Tumors

  • Bladder Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors

  • Colorectal Cancer, Endometrial Cancer, Gastric (Stomach) Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Bladder Cancer, Breast Cancer, Cervical Cancer

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

  • Endometrial Cancer, Bladder Cancer

22-660          Phase I

An Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations

  • Lung Cancer, Bladder Cancer, Head and Neck Cancer, Lymphoma

19-500          Phase I

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma

Showing 1 - 10 of 13 results